Bioreclamation and CelsisIVT Combine to Create BioreclamationIVT
News Aug 29, 2013
Bioreclamation Group, Inc. announced it has acquired Celsis In Vitro Technologies (“CelsisIVT”), a division of Celsis International Ltd. and a provider of in vitro products for the study of drug metabolism and toxicity. Brown Gibbons Lang & Company represented the Maryland-based CelsisIVT in the transaction. Terms of the deal were not disclosed.
The two companies will combine to become BioreclamationIVT, creating a one-stop shop offering a complete range of biological tools needed to pursue new drug discovery and development. The combined Companies’ highly specialized products enable researchers to better understand the pharmacokinetics and metabolism of newly discovered compounds. BioreclamationIVT’s sophisticated sourcing and exceptional quality control processes help reduce the time and cost of screening drug compounds in early-stage drug discovery and development.
Integrated Lead Discovery: An Evolving ToolboxNews
A new SLAS Discovery review article offers an informative guide to the established and emerging tools available for early drug discovery and screening, and provides illustrative scenarios demonstrating considerations that drive decisions on choice of lead discovery tactics.READ MORE
Comments | 0 ADD COMMENT
10th Annual Congress on Drug Formulation & Analytical Techniques
Sep 03 - Sep 04, 2018